Opioids and anxiety

Journal of Psychopharmacology

Volumn 25, Issue 11, 2011, Pages 1415-1433

  Colasanti, A ^a,b,c   Rabiner, E A ^c   Lingford Hughes, A ^a   Nutt, D J ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Antidepressants; anxiolytics; dynorphin; endorphin; enkephalin; neurobiology; obsessive compulsive; opioid receptors; panic disorder; phobias; PTSD

Indexed keywords

4 AMINOBUTYRIC ACID; ANTIDEPRESSANT AGENT; DIAZEPAM; FLUOXETINE; MORPHINE; NALMEFENE; NALOXONE; NALTREXONE; OPIATE; OPIATE RECEPTOR; PAROXETINE; PLACEBO; SEROTONIN; VENLAFAXINE;

AMYGDALOID NUCLEUS; ANALGESIC ACTIVITY; ANXIETY; ANXIETY DISORDER; CLINICAL TRIAL (TOPIC); DEFENSIVE BEHAVIOR; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; FEAR; GABAERGIC SYSTEM; HUMAN; HYPOTHALAMUS; LIGAND BINDING; LOW DRUG DOSE; MEDICAL LITERATURE; MESENCEPHALON; NEUROBIOLOGY; NEUROMODULATION; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; OPIATE ADDICTION; PANIC; PATHOPHYSIOLOGY; PHOBIA; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; REVIEW; SINGLE DRUG DOSE; SPIDER PHOBIA; TRANQUILIZING ACTIVITY; TRICHOTILLOMANIA;

ANALGESICS, OPIOID; ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; HUMANS; NEUROBIOLOGY; NEUROIMAGING;

EID: 83455162327     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881110367726     Document Type: Review

References (189)

1. Agmo A, Galvan A, Heredia A, Morales M. Naloxone blocks the antianxiety but not the motor effects of benzodiazepines and pentobarbital: experimental studies and literature review. Psychopharmacology (Berl). 1995 ; 120: 186-194
2. Amiaz R, Fostick L, Gershon A, Zohar J. Naltrexone augmentation in OCD: a double-blind placebo-controlled cross-over study. Eur Neuropsychopharmacol. 2008 ; 18: 455-461
3. DSM-IV-TR Diagnostic and Statistic Manual of Mental Disorders, Fourth Edition, Text Revision. 2000 ) DSM-IV-TR Diagnostic and Statistic Manual of Mental Disorders, Fourth Edition, Text Revision, 4th edn. Washington, DC: American Psychiatric Association. Washington, DC: American Psychiatric Association ; 2000 :
4. Arntz A. Endorphins stimulate approach behaviour, but do not reduce subjective fear. A pilot study. Behav Res Ther. 1993 ; 31: 403-405 (Pubitemid 23152643)
5. Arntz A, Merckelbach H, de Jong P. Opioid antagonist affects behavioral effects of exposure in vivo. J Consult Clin Psychol. 1993 ; 61: 865-870 (Pubitemid 23304599)
6. Asakawa A, Inui A, Momose K, Ueno N, Fujino MA, Kasuga M. Endomorphins have orexigenic and anxiolytic activities in mice. Neuroreport. 1998 ; 9: 2265-2267 (Pubitemid 28338218)
7. Aston-Jones G, Harris GC. Brain substrates for increased drug seeking during protracted withdrawal. Neuropharmacology 47. 2004 ; (Suppl 1). 167-179 (Pubitemid 39298262)
8. Baker DG, West SA, Orth DN, et al. Cerebrospinal fluid and plasma beta-endorphin in combat veterans with post-traumatic stress disorder. Psychoneuroendocrinology. 1997 ; 22: 517-529 (Pubitemid 27505111)
9. Bals-Kubik R, Herz A, Shippenberg TS. Evidence that the aversive effects of opioid antagonists and kappa-agonists are centrally mediated. Psychopharmacology (Berl). 1989 ; 98: 203-206 (Pubitemid 19137732)
10. Bechara A, van der Kooy D. Kappa receptors mediate the peripheral aversive effects of opiates. Pharmacol Biochem Behav. 1987 ; 28: 227-233 (Pubitemid 17158215)
11. Becker WC, Sullivan LE, Tetrault JM, Desai RA, Fiellin DA. Non-medical use, abuse and dependence on prescription opioids among U.S. adults: psychiatric, medical and substance use correlates. Drug Alcohol Depend. 2008 ; 94: 38-47
12. Bendick J Galen and the Gateway to Medicine. Bathgate, ND: Betlehem Books ; 2002 :
13. Berrocoso E, Mico JA. Cooperative opioid and serotonergic mechanisms generate superior antidepressant-like effects in a mice model of depression. Int J Neuropsychopharmacol. 2009 ; 12: 1-12
14. Berrocoso E, Rojas-Corrales MO, Mico JA. Non-selective opioid receptor antagonism of the antidepressant-like effect of venlafaxine in the forced swimming test in mice. Neurosci Lett. 2004 ; 363: 25-28 (Pubitemid 38639845)
15. Bilkei-Gorzo A, Racz I, Michel K, Zimmer A, Klingmuller D, Zimmer A. Behavioral phenotype of pre-proenkephalin-deficient mice on diverse congenic backgrounds. Psychopharmacology (Berl). 2004 ; 176: 343-352 (Pubitemid 40012741)
16. Billingsley ML, Kubena RK. The effects of naloxone and picrotoxin on the sedative and anticonflict effects of benzodiazepines. Life Sci. 1978 ; 22: 897-906 (Pubitemid 8305174)
17. Bills LJ, Kreisler K. Treatment of flashbacks with naltrexone. Am J Psychiatry. 1993 ; 150: 1430-1430
18. Blackburn TP, Cross AJ, Hille C, Slater P. Autoradiographic localization of delta opiate receptors in rat and human brain. Neuroscience. 1988 ; 27: 497-506
19. Bohus MJ, Landwehrmeyer GB, Stiglmayr CE, Limberger MF, Bohme R, Schmahl CG. Naltrexone in the treatment of dissociative symptoms in patients with borderline personality disorder: an open-label trial. J Clin Psychiatry. 1999 ; 60: 598-603 (Pubitemid 29451556)
20. Borsook D, Hyman SE. Proenkephalin gene regulation in the neuroendocrine hypothalamus: a model of gene regulation in the CNS. Am J Physiol. 1995 ; 269: E393-408
21. Brady KT, Lydiard RB, Ballenger JC, Shook J, Laraia M, Fossey M. CSF opioids in panic disorder. Biol Psychiatry. 1991 ; 30: 512-514
22. Brandão ML, Anseloni VZ, Pandossio JE, De Araujo JE, Castilho VM. Neurochemical mechanisms of the defensive behavior in the dorsal midbrain. Neurosci Biobehav Rev. 1999 ; 23: 863-875 (Pubitemid 29458892)
23. Brandão ML, Tomaz C, Borges PC, Coimbra NC, Bagri A. Defense reaction induced by microinjections of bicuculline into the inferior colliculus. Physiol Behav. 1988 ; 44: 361-365 (Pubitemid 19006985)
24. Brandão ML, Troncoso AC, de Souza Silva MA, Huston JP. The relevance of neuronal substrates of defense in the midbrain tectum to anxiety and stress: empirical and conceptual considerations. Eur J Pharmacol. 2003 ; 463: 225-233 (Pubitemid 36205083)
25. Briggs AC, Stretch DD, Brandon S. Subtyping of panic disorder by symptom profile. Br J Psychiatry. 1993 ; 163: 201-209 (Pubitemid 23233089)
26. Burghardt PR, Wilson MA. Microinjection of naltrexone into the central, but not the basolateral, amygdala blocks the anxiolytic effects of diazepam in the plus maze. Neuropsychopharmacology. 2006 ; 3: 1227-1240 (Pubitemid 43971839)
27. Calvo F, Coimbra NC. Interactions between opioid-peptides-containing pathways and GABA(A)-receptors-mediated systems modulate panic-like-induced behaviors elicited by electric and chemical stimulation of the inferior colliculus. Brain Res. 2006 ; 1104: 92-102 (Pubitemid 44164433)
28. Carr DB, Sheehan DV, Surman OS, et al. Neuroendocrine correlates of lactate-induced anxiety and their response to chronic alprazolam therapy. Am J Psychiatry. 1986 ; 143: 483-494 (Pubitemid 16119755)
29. Castellan-Baldan L, da Costa Kawasaki M, Ribeiro SJ, Calvo F, Corrêa VM, Coimbra NC. Topographic and functional neuroanatomical study of GABAergic disinhibitory striatum-nigral inputs and inhibitory nigrocollicular pathways: neural hodology recruiting the substantia nigra, pars reticulata, for the modulation of the neural activity in the inferior colliculus involved with panic-like emotions. J Chem Neuroanat. 2006 ; 32: 1-27 (Pubitemid 44234003)
30. Charney DS, Heninger GR. Alpha 2-adrenergic and opiate receptor blockade. Synergistic effects on anxiety in healthy subjects. Arch Gen Psychiatry. 1986 ; 43: 1037-1041 (Pubitemid 17173224)
31. Cohen MR, Cohen RM, Pickar D, Weingartner H, Murphy DL. High-dose naloxone infusions in normals. Dose-dependent behavioral, hormonal, and physiological responses. Arch Gen Psychiatry. 1983 ; 40: 613-619 (Pubitemid 13094928)
32. Colasanti A, Salamon E, Schruers K, Van Diest R, Van Duinen M, Griez EJ. Carbon dioxide-induced emotion and respiratory symptoms in healthy volunteers. Neuropsychopharmacology. 2008 ; 33: 3103-3110
33. Comings DE, Dietz G, Gade-Andavolu R, et al. Association of the neutral endopeptidase (MME) gene with anxiety. Psychiatr Genet. 2000 ; 10: 91-94 (Pubitemid 32000907)
34. Conway KP, Compton W, Stinson FS, Grant BF. Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2006 ; 67: 247-257 (Pubitemid 43357471)
35. Da Silva LF, Menescal-de-Oliveira L. Role of opioidergic and GABAergic neurotransmission of the nucleus raphe magnus in the modulation of tonic immobility in guinea pigs. Brain Res Bull. 2007 ; 72: 25-31
36. Dager SR, Cowley DS, Dorsa DM, Dunner DL. Plasma beta-endorphin response to lactate infusion. Biol Psychiatry. 1989 ; 25: 243-245 (Pubitemid 19034963)
37. Darko DF, Risch SC, Gillin JC, Golshan S. Association of beta-endorphin with specific clinical symptoms of depression. Am J Psychiatry. 1992 ; 149: 1162-1167
38. Daunais JB, Letchworth SR, Sim-Selley LJ, Smith HR, Childers SR, Porrino LJ. Functional and anatomical localization of mu opioid receptors in the striatum, amygdala, and extended amygdala of the nonhuman primate. J Comp Neurol. 2001 ; 433: 471-485 (Pubitemid 32336570)
39. Del-Ben CM, Graeff FG. Panic disorder: is the PAG involved?. Neural Plast. 2009 ; 2009: 1-9
40. Dreborg S, Sundstrom G, Larsson TA, Larhammar D. Evolution of vertebrate opioid receptors. Proc Natl Acad Sci USA. 2008 ; 105: 15487-15492
41. Drolet G, Dumont EC, Gosselin I, Kinkead R, Laforest S, Trottier JF. Role of endogenous opioid system in the regulation of the stress response. Prog Neuropsychopharmacol Biol Psychiatry. 2001 ; 25: 729-741 (Pubitemid 32377292)
42. Duka T, Millan MJ, Ulsamer B, Doenicke A. Naloxone attenuates the anxiolytic action of diazepam in man. Life Sci. 1982 ; 31: 1833-1836 (Pubitemid 13210364)
43. Duman EN, Kesim M, Kadioglu M, Yaris E, Kalyoncu NI, Erciyes N. Possible involvement of opioidergic and serotonergic mechanisms in antinociceptive effect of paroxetine in acute pain. J Pharmacol Sci. 2004 ; 94: 161-165 (Pubitemid 38405130)
44. Egan KJ, Carr JE, Hunt DD, Adamson R. Endogenous opiate system and systematic desensitization. J Consult Clin Psychol. 1988 ; 56: 287-291
45. Eichenberger GC, Ribeiro SJ, Osaki MY, et al. Neuroanatomical and psychopharmacological evidence for interaction between opioid and GABAergic neural pathways in the modulation of fear and defense elicited by electrical and chemical stimulation of the deep layers of the superior colliculus and dorsal periaqueductal gray matter. Neuropharmacology. 2002 ; 42: 48-59 (Pubitemid 34062821)
46. Eriksson E, Westberg P, Thuresson K, Modigh K, Ekman R, Widerlov E. Increased cerebrospinal fluid levels of endorphin immunoreactivity in panic disorder. Neuropsychopharmacology. 1989 ; 2: 225-228 (Pubitemid 19248314)
47. Erjavec MK, Coda BA, Nguyen Q, Donaldson G, Risler L, Shen DD. Morphine-fluoxetine interactions in healthy volunteers: analgesia and side effects. J Clin Pharmacol. 2000 ; 40: 1286-1295
48. Esquivel G, Fernandez-Torre O, Schruers KR, Wijnhoven LL, Griez EJ. The effects of opioid receptor blockade on experimental panic provocation with CO2. J Psychopharmacol. 2009a ; 23 (8). 975-978
49. Esquivel G, Schruers KR, Maddock RJ, Colasanti A and Griez EJ (2009b) Acids in the brain: a factor in panic? J Psychopharmacol May 21.
50. Faber ES, Sah P. Opioids inhibit lateral amygdala pyramidal neurons by enhancing a dendritic potassium current. J Neurosci. 2004 ; 24: 3031-3039 (Pubitemid 38405750)
51. Fanselow MS, Bolles RC. Naloxone and shock-elicited freezing in the rat. J Comp Physiol Psychol. 1979 ; 93: 736-744 (Pubitemid 9248583)
52. File SE, Rodgers RJ. Partial anxiolytic action of morphine sulphate following microinjection into the central nucleus of the amygdala in rats. Pharmacol Biochem Behav. 1979 ; 11: 313-318 (Pubitemid 10194818)
53. Filliol D, Ghozland S, Chluba J, et al. Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses. Nat Genet. 2000 ; 25: 195-200 (Pubitemid 30394992)
54. Friedman I, Dar R, Shilony E. Compulsivity and obsessionality in opioid addiction. J Nerv Ment Dis. 2000 ; 188: 155-162 (Pubitemid 30159866)
55. Frost JJ, Douglass KH, Mayberg HS, et al. Multicompartmental analysis of [11C]-carfentanil binding to opiate receptors in humans measured by positron emission tomography. J Cereb Blood Flow Metab. 1989 ; 9: 398-409 (Pubitemid 19134817)
56. Gallagher M, Kapp BS. Manipulation of opiate activity in the amygdala alters memory processes. Life Sci. 1978 ; 23: 1973-1977 (Pubitemid 9078774)
57. Gallagher M, Kapp BS, McNall CL, Pascoe JP. Opiate effects in the amygdala central nucleus on heart rate conditioning in rabbits. Pharmacol Biochem Behav. 1981 ; 14: 497-505 (Pubitemid 11107505)
58. George DT, Adinoff B, Ravitz B, et al. A cerebrospinal fluid study of the pathophysiology of panic disorder associated with alcoholism. Acta Psychiatr Scand. 1990 ; 82: 1-7 (Pubitemid 20244532)
59. Glover H. A preliminary trial of nalmefene for the treatment of emotional numbing in combat veterans with post-traumatic stress disorder. Isr J Psychiatry Relat Sci. 1993 ; 30: 255-263 (Pubitemid 24039004)
60. Gold MS, Pottash AC, Sweeney D, Martin D, Extein I. Antimanic, antidepressant, and antipanic effects of opiates: clinical, neuroanatomical, and biochemical evidence. Ann N Y Acad Sci. 1982 ; 398: 140-150 (Pubitemid 13026043)
61. Gold MS, Pottash AL, Sweeney DR, Davies RK, Kleber HD. Clonidine decreases opiate withdrawal-related anxiety: possible opiate noradrenergic interaction in anxiety and panic. Subst Alcohol Actions Misuse. 1980 ; 1: 239-246 (Pubitemid 11224316)
62. Gold MS, Pottash AL, Sweeney DR, Kleber HD, Redmond DE. Rapid opiate detoxification: clinical evidence of antidepressant and antipanic effects of opiates. Am J Psychiatry. 1979 ; 136: 982-983 (Pubitemid 9201228)
63. Goldsmith TB, Shapira NA, Keck PE. Rapid remission of OCD with tramadol hydrochloride. Am J Psychiatry. 1999 ; 156: 660-661 (Pubitemid 29162995)
64. Good AJ, Westbrook RF. Effects of a microinjection of morphine into the amygdala on the acquisition and expression of conditioned fear and hypoalgesia in rats. Behav Neurosci. 1995 ; 109: 631-641
65. Goodwin RD, Pine DS. Respiratory disease and panic attacks among adults in the United States. Chest. 2002 ; 122: 645-650 (Pubitemid 35002149)
66. Gray AM, Spencer PS, Sewell RD. The involvement of the opioidergic system in the antinociceptive mechanism of action of antidepressant compounds. Br J Pharmacol. 1998 ; 124: 669-674 (Pubitemid 28276803)
67. Grevert P, Goldstein A. Effects of naloxone on experimentally induced ischemic pain and on mood in human subjects. Proc Natl Acad Sci USA. 1977 ; 74: 1291-1294 (Pubitemid 8065653)
68. Grevert P, Goldstein A. Endorphins: naloxone fails to alter experimental pain or mood in humans. Science. 1978 ; 199: 1093-1095 (Pubitemid 8311095)
69. Griez EJ, Colasanti A, van Diest R, Salamon E, Schruers K. Carbon dioxide inhalation induces dose-dependent and age-related negative affectivity. PLos One. 2007 ; 2 (10). e987 - e987
70. Griez E, Lousberg H, Van den Hout MA, Van der Molen MG. CO2 vulnerability in panic disorder. Psychiatry Res. 1987 ; 20: 87-95
71. Gultekin H, Ahmedov V. Role of the opioidergic system and nitric oxide in the analgesic effect of venlafaxine. Yakugaku Zasshi. 2006 ; 126: 117-121 (Pubitemid 43171743)
72. Haertzen CA, Meketon MJ, Hooks NT. Subjective experiences produced by the withdrawal of opiates. Br J Addict Alcohol Other Drugs. 1970 ; 65: 245-255
73. Hamner MB, Hitri A. Plasma beta-endorphin levels in post-traumatic stress disorder: a preliminary report on response to exercise-induced stress. J Neuropsychiatry Clin Neurosci. 1992 ; 4: 59-63
74. Harsing LG, Yang HY, Costa E. Evidence for a gamma-aminobutyric acid (GABA) mediation in the benzodiazepine inhibition of the release of Met5-enkephalin elicited by depolarization. J Pharmacol Exp Ther. 1982 ; 220: 616-620 (Pubitemid 12152177)
75. Hebb AL, Poulin JF, Roach SP, Zacharko RM, Drolet G. Cholecystokinin and endogenous opioid peptides: interactive influence on pain, cognition, and emotion. Prog Neuropsychopharmacol Biol Psychiatry. 2005 ; 29: 1225-1238 (Pubitemid 41674637)
76. Hebb AL, Zacharko RM, Gauthier M, Trudel F, Laforest S, Drolet G. Brief exposure to predator odor and resultant anxiety enhances mesocorticolimbic activity and enkephalin expression in CD-1 mice. Eur J Neurosci. 2004 ; 20: 2415-2429 (Pubitemid 39472403)
77. Hoffman L, Burges Watson P, Wilson G, Montgomery J. Low plasma beta-endorphin in post-traumatic stress disorder. Aust N Z J Psychiatry. 1989 ; 23: 269-273 (Pubitemid 19176208)
78. Ibarra P, Bruehl SP, McCubbin JA, et al. An unusual reaction to opioid blockade with naltrexone in a case of post-traumatic stress disorder. J Trauma Stress. 1994 ; 7: 303-309 (Pubitemid 24256300)
79. Insel TR, Pickar D. Naloxone administration in obsessive-compulsive disorder: report of two cases. Am J Psychiatry. 1983 ; 140 (9). 1219-1220 (Pubitemid 13050743)
80. Jasinski DR, Johnson RE, Kocher TR. Clonidine in morphine withdrawal. Differential effects on signs and symptoms. Arch Gen Psychiatry. 1985 ; 42: 1063-1066
81. Jenck F, Schmitt P, Karli P. Morphine injected into the periaqueductal gray attenuates brain stimulation-induced effects: an intensity discrimination study. Brain Res. 1986 ; 378: 274-284 (Pubitemid 16055565)
82. Kang W, Wilson SP, Wilson MA. Overexpression of proenkephalin in the amygdala potentiates the anxiolytic effects of benzodiazepines. Neuropsychopharmacology. 2000 ; 22: 77-88
83. Kennedy SE, Koeppe RA, Young EA, Zubieta JK. Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women. Arch Gen Psychiatry. 2006 ; 63: 1199-1208 (Pubitemid 44708077)
84. Keuler DJ, Altemus M, Michelson D, Greenberg B, Murphy DL. Behavioral effects of naloxone infusion in obsessive-compulsive disorder. Biol Psychiatry. 1996 ; 40: 154-156 (Pubitemid 26202448)
85. Khachaturian H, Lewis ME, Haber SN, Akil H, Watson SJ. Proopiomelanocortin peptide immunocytochemistry in rhesus monkey brain. Brain Res Bull. 1984 ; 13: 785-800 (Pubitemid 15090397)
86. Khachaturian H, Lewis ME, Haber SN, Houghten RA, Akil H, Watson SJ. Prodynorphin peptide immunocytochemistry in rhesus monkey brain. Peptides. 1985 ; 6 (Suppl 2). 155-166 (Pubitemid 16211122)
87. Khazaal Y, Despland JN, Currat T, Zullino DF. Obsessive-compulsive symptoms precipitated by methadone tapering. J Clin Psychopharmacol. 2004 ; 24: 682-683 (Pubitemid 39518674)
88. Khazaal Y, Krenz S, Benmebarek M, Zullino DF. Worsening of obsessive-compulsive symptoms under methadone tapering. Prog Neuropsychopharmacol Biol Psychiatry. 2006 ; 30: 1350-1352 (Pubitemid 44216053)
89. Kieffer BL. Opioids: first lessons from knockout mice. Trends Pharmacol Sci. 1999 ; 20: 19-26 (Pubitemid 29304521)
90. Kirouac GJ, Li S, Mabrouk G. GABAergic projection from the ventral tegmental area and substantia nigra to the periaqueductal gray region and the dorsal raphe nucleus. J Comp Neurol. 2004 ; 469: 170-184 (Pubitemid 38083868)
91. Koepp MJ, Hammers A, Lawrence AD, Asselin MC, Grasby PM, Bench CJ. Evidence for endogenous opioid release in the amygdala during positive emotion. Neuroimage. 2009 ; 44: 252-256
92. Koks S, Soosaar A, Voikar V, Bourin M, Vasar E. BOC-CCK-4, CCK(B)receptor agonist, antagonizes anxiolytic-like action of morphine in elevated plus-maze. Neuropeptides. 1999 ; 33: 63-69 (Pubitemid 29248966)
93. Konig M, Zimmer AM, Steiner H, et al. Pain responses, anxiety and aggression in mice deficient in pre-proenkephalin. Nature. 1996 ; 383: 535-538 (Pubitemid 26346181)
94. Koob GF, Le Moal M. Plasticity of reward neurocircuitry and the 'dark side' of drug addiction. Nat Neurosci. 2005 ; 8: 1442-1444 (Pubitemid 41573653)
95. Koran LM, Aboujaoude E, Bullock KD, Franz B, Gamel N, Elliott M. Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2005 ; 66: 353-359 (Pubitemid 40476759)
96. Kozak AT, Spates CR, McChargue DE, Bailey KC, Schneider KL, Liepman MR. Naltrexone renders one-session exposure therapy less effective: a controlled pilot study. J Anxiety Disord. 2007 ; 21: 142-152 (Pubitemid 46109575)
97. LeDoux J. The emotional brain, fear, and the amygdala. Cell Mol Neurobiol. 2003 ; 23: 727-738
98. Liberzon I, Taylor SF, Phan KL, et al. Altered central micro-opioid receptor binding after psychological trauma. Biol Psychiatry. 2007 ; 61: 1030-1038 (Pubitemid 46551967)
99. Liberzon I, Zubieta JK, Fig LM, Phan KL, Koeppe RA, Taylor SF. mu-Opioid receptors and limbic responses to aversive emotional stimuli. Proc Natl Acad Sci U S A. 2002 ; 99: 7084-7089 (Pubitemid 34526259)
100. Liebowitz MR, Gorman JM, Fyer AJ, Dillon DJ, Klein DF. Effects of naloxone on patients with panic attacks. Am J Psychiatry. 1984 ; 141: 995-997 (Pubitemid 14093711)
101. Lord JA, Waterfield AA, Hughes J, Kosterlitz HW. Endogenous opioid peptides: multiple agonists and receptors. Nature. 1977 ; 267: 495-499 (Pubitemid 8098466)
102. Lubin G, Weizman A, Shmushkevitz M, Valevski A. Short-term treatment of post-traumatic stress disorder with naltrexone: an open-label preliminary study. Hum Psychopharmacol. 2002 ; 17: 181-185 (Pubitemid 34678879)
103. Luby ED, Marrazzi MA. A panic attack precipitated by opiate blockade-a case study. J Clin Psychopharmacol. 1987 ; 7: 361-362
104. Mangold DL, Peyrot M, Giggey P, Wand GS. Endogenous opioid activity is associated with obsessive-compulsive symptomology in individuals with a family history of alcoholism. Neuropsychopharmacology. 2000 ; 22: 595-607 (Pubitemid 30219403)
105. Mansour A, Fox CA, Akil H, Watson SJ. Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications. Trends Neurosci. 1995a ; 18: 22-29
106. Mansour A, Fox CA, Burke S, Akil H, Watson SJ. Immunohistochemical localization of the cloned mu opioid receptor in the rat CNS. J Chem Neuroanat. 1995b ; 8: 283-305
107. Mansour A, Fox CA, Burke S, et al. Mu, delta, and kappa opioid receptor mRNA expression in the rat CNS: an in situ hybridization study. J Comp Neurol. 1994 ; 350: 412-438 (Pubitemid 24356007)
108. Mansour A, Khachaturian H, Lewis ME, Akil H, Watson SJ. Autoradiographic differentiation of mu, delta, and kappa opioid receptors in the rat forebrain and midbrain. J Neurosci. 1987 ; 7: 2445-2464
109. Mansour A, Khachaturian H, Lewis ME, Akil H, Watson SJ. Anatomy of CNS opioid receptors. Trends Neurosci. 1988 ; 11: 308-314
110. Maremmani I, Marini G, Fornai F. Naltrexone-induced panic attacks. Am J Psychiatry. 1998 ; 155: 447-447
111. Martin del Campo AF, Cortes-Sotres J, Herrera-Ferra K, Ulloa-Aguirre A. High-dose naloxone (1.0mg/kg): psychological and endocrine effects in normal male subjects pretreated with one milligram of dexamethasone. Psychoneuroendocrinology. 1998 ; 23: 413-424 (Pubitemid 28355755)
112. Martin del Campo AF, Dowson JH, Herbert J, Paykel ES. Effects of naloxone on diurnal rhythms in mood and endocrine function: a dose-response study in man. Psychopharmacology (Berl). 1994 ; 114: 583-590 (Pubitemid 24152138)
113. Martin del Campo AF, Granados-Soto V, Aguirre-Banuelos P, Cardenas M, Castaneda-Hernandez G. The use of the plasma concentration-effect relationship as a tool for the study of the mechanism of action of naloxone effects on mood and endocrine function. J Psychopharmacol. 1997 ; 11: 361-365 (Pubitemid 27526045)
114. Martin del Campo AF, McMurray RG, Besser GM, Grossman A. Effect of 12-hour infusion of naloxone on mood and cognition in normal male volunteers. Biol Psychiatry. 1992 ; 32: 344-353
115. Melichar JK, Malizia AL, Nutt DJ. Organization of opioid receptors in human brain and drug interactions studied by PET and SPECT imaging: implications for treatment strategies for opiate addiction. Seminars in Neurosciences. 1997 ; 9: 131-139 (Pubitemid 27490189)
116. Melichar JK, Nutt DJ, Malizia AL. Naloxone displacement at opioid receptor sites measured in vivo in the human brain. Eur J Pharmacol. 2003 ; 459: 217-219 (Pubitemid 36078324)
117. Merluzzi TV, Taylor CB, Boltwood M, Gotestam KG. Opioid antagonist impedes exposure. J Consult Clin Psychol. 1991 ; 59: 425-430
118. Mogil JS, Pasternak GW. The molecular and behavioral pharmacology of the orphanin FQ/nociceptin peptide and receptor family. Pharmacol Rev. 2001 ; 53: 381-415 (Pubitemid 32852018)
119. Motta V, Brandão ML. Aversive and antiaversive effects of morphine in the dorsal periaqueductal gray of rats submitted to the elevated plus-maze test. Pharmacol Biochem Behav. 1993 ; 44: 119-125
120. Motta V, Penha K, Brandão ML. Effects of microinjections of mu and kappa receptor agonists into the dorsal periaqueductal gray of rats submitted to the plus maze test. Psychopharmacology (Berl). 1995 ; 120: 470-474
121. Mucha RF, Herz A. Motivational properties of kappa and mu opioid receptor agonists studied with place and taste preference conditioning. Psychopharmacology (Berl). 1985 ; 86: 274-280 (Pubitemid 15064950)
122. Murphy RB, Pincus MR, Beinfeld M, et al. Enkephalin is a competitive antagonist of cholecystokinin in the gastrointestinal tract, as predicted from prior conformational analysis. J Protein Chem. 1992 ; 11: 723-729
123. Narita M, Kaneko C, Miyoshi K, et al. Chronic pain induces anxiety with concomitant changes in opioidergic function in the amygdala. Neuropsychopharmacology. 2006 ; 31: 739-750
124. Nashold BS, Wilson WP, Slaughter DG. Sensations evoked by stimulation in the midbrain of man. J Neurosurg. 1969 ; 30: 14-24
125. Nobre MJ, Ribeiro dos Santos N, Aguiar MS, Brandão ML. Blockade of mu- and activation of kappa-opioid receptors in the dorsal periaqueductal gray matter produce defensive behavior in rats tested in the elevated plus-maze. Eur J Pharmacol. 2000 ; 404: 145-151
126. Nutt DJ Anxiety Disorders An Introduction to Clinical Management and Research. Griez EJLF C Nutt D Zohar J, ed. Chichester: Wiley ; 2001: 310-310.
127. Osaki MY, Castellan-Baldan L, Calvo F, et al. Neuroanatomical and neuropharmacological study of opioid pathways in the mesencephalic tectum: effect of mu(1)- and kappa-opioid receptor blockade on escape behavior induced by electrical stimulation of the inferior colliculus. Brain Res. 2003 ; 992: 179-192 (Pubitemid 37415101)
128. Paden CM, Krall S, Lynch WC. Heterogeneous distribution and upregulation of mu, delta and kappa opioid receptors in the amygdala. Brain Res. 1987 ; 418: 349-355 (Pubitemid 17145258)
129. Papageorgiou C, Rabavilas A, Liappas I, Stefanis C. Do obsessive-compulsive patients and abstinent heroin addicts share a common psychophysiological mechanism?. Neuropsychobiology. 2003 ; 47: 1-11 (Pubitemid 36469779)
130. Papp LA, Martinez JM, Klein DF, et al. Respiratory psychophysiology of panic disorder: three respiratory challenges in 98 subjects. Am J Psychiatry. 1997 ; 154: 1557-1565 (Pubitemid 27471349)
131. Peckys D, Landwehrmeyer GB. Expression of mu, kappa, and delta opioid receptor messenger RNA in the human CNS: a 33P in situ hybridization study. Neuroscience. 1999 ; 88: 1093-1135 (Pubitemid 28546992)
132. Peoples RW, Giridhar J, Isom GE. Gamma-aminobutyric acidA (GABAA) receptor modulation of morphine inhibition of norepinephrine release. Biochem Pharmacol. 1991 ; 42 (Suppl). S121-126
133. Pert CB, Snyder SH. Properties of opiate-receptor binding in rat brain. Proc Natl Acad Sci U S A. 1973 ; 70: 2243-2247
134. Pickar D, Cohen MR, Naber D, Cohen RM. Clinical studies of the endogenous opioid system. Biol Psychiatry. 1982 ; 17: 1243-1276 (Pubitemid 13255056)
135. Pilapil C, Welner S, Magnan J, Gauthier S, Quirion R. Autoradiographic distribution of multiple classes of opioid receptor binding sites in human forebrain. Brain Res Bull. 1987 ; 19: 611-615
136. Pine DS, Weese-Mayer DE, Silvestri JM, Davies M, Whitaker AH, Klein DF. Anxiety and congenital central hypoventilation syndrome. Am J Psychiatry. 1994 ; 151: 864-870
137. Pitman RK, van der Kolk BA, Orr SP, Greenberg MS. Naloxone-reversible analgesic response to combat-related stimuli in posttraumatic stress disorder. A pilot study. Arch Gen Psychiatry. 1990 ; 47: 541-544 (Pubitemid 20189966)
138. Poulin JF, Chevalier B, Laforest S, Drolet G. Enkephalinergic afferents of the centromedial amygdala in the rat. J Comp Neurol. 2006 ; 496: 859-876
139. Preter M, Klein DF. Panic, suffocation, false alarms, separation anxiety and endogenous opioids. Prog Neuropsychopharmacol Biol Psychiatry. 2008 ; 32: 603-612 (Pubitemid 351312351)
140. Primeaux SD, Wilson SP, McDonald AJ, Mascagni F, Wilson MA. The role of delta opioid receptors in the anxiolytic actions of benzodiazepines. Pharmacol Biochem Behav. 2006 ; 85: 545-554 (Pubitemid 46097065)
141. Ragnauth A, Schuller A, Morgan M, et al. Female preproenkephalin-knockout mice display altered emotional responses. Proc Natl Acad Sci U S A. 2001 ; 98: 1958-1963 (Pubitemid 32165605)
142. Reichenberg K, Gaillard-Plaza G, Montastruc JL. Influence of naloxone on the antinociceptive effects of some antidepressant drugs. Arch Int Pharmacodyn Ther. 1985 ; 275: 78-85 (Pubitemid 15013569)
143. Rezvani A, Stokes KB, Rhoads DL, Way EL. Proglumide exhibits delta opioid agonist properties. Alcohol Drug Res. 1987 ; 7: 135-146 (Pubitemid 17034317)
144. Ribeiro SC, Kennedy SE, Smith YR, Stohler CS, Zubieta JK. Interface of physical and emotional stress regulation through the endogenous opioid system and mu-opioid receptors. Prog Neuropsychopharmacol Biol Psychiatry. 2005a ; 29: 1264-1280 (Pubitemid 41679306)
145. Ribeiro SJ, Ciscato JG, de Oliveira R, et al. Functional and ultrastructural neuroanatomy of interactive intratectal/tectonigral mesencephalic opioid inhibitory links and nigrotectal GABAergic pathways: involvement of GABAA and mu1-opioid receptors in the modulation of panic-like reactions elicited by electrical stimulation of the dorsal midbrain. J Chem Neuroanat. 2005b ; 30: 184-200 (Pubitemid 41579110)
146. Rose C, Vargas F, Facchinetti P, et al. Characterization and inhibition of a cholecystokinin-inactivating serine peptidase. Nature. 1996 ; 380: 403-409 (Pubitemid 26102716)
147. Roy BF, Benkelfat C, Hill JL, et al. Serum antibody for somatostatin-14 and prodynorphin 209-240 in patients with obsessive-compulsive disorder, schizophrenia, Alzheimer's disease, multiple sclerosis, and advanced HIV infection. Biol Psychiatry. 1994 ; 35: 335-344 (Pubitemid 24150269)
148. Sandyk R. Naloxone abolishes obsessive-compulsive behavior in Tourette's syndrome. Int J Neurosci. 1987 ; 35: 93-94
149. Santiago TV, Edelman NH. Opioids and breathing. J Appl Physiol. 1985 ; 59: 1675-1685
150. Saxe G, Geary M, Bedard K, et al. Separation anxiety as a mediator between acute morphine administration and PTSD symptoms in injured children. Ann N Y Acad Sci. 2006 ; 1071: 41-45 (Pubitemid 44126718)
151. Saxe G, Stoddard F, Courtney D, et al. Relationship between acute morphine and the course of PTSD in children with burns. J Am Acad Child Adolesc Psychiatry. 2001 ; 40: 915-921 (Pubitemid 32667074)
152. Schreiber S, Backer MM, Pick CG. The antinociceptive effect of venlafaxine in mice is mediated through opioid and adrenergic mechanisms. Neurosci Lett. 1999 ; 273: 85-88 (Pubitemid 29428113)
153. Schulteis G, Koob GF. Reinforcement processes in opiate addiction: a homeostatic model. Neurochem Res. 1996 ; 21: 1437-1454 (Pubitemid 26397074)
154. Self DW, Nestler EJ. Relapse to drug-seeking: neural and molecular mechanisms. Drug Alcohol Depend. 1998 ; 51: 49-60 (Pubitemid 28353755)
155. Shaikh MB, Lu CL, Siegel A. An enkephalinergic mechanism involved in amygdaloid suppression of affective defence behavior elicited from the midbrain periaqueductal gray in the cat. Brain Res. 1991 ; 559: 109-117
156. Shapira NA, Keck PE, Goldsmith TD, McConville BJ, Eis M, McElroy SL. Open-label pilot study of tramadol hydrochloride in treatment-refractory obsessive-compulsive disorder. Depress Anxiety. 1997 ; 6: 170-173 (Pubitemid 28164822)
157. Singh VP, Jain NK, Kulkarni SK. On the antinociceptive effect of fluoxetine, a selective serotonin reuptake inhibitor. Brain Res. 2001 ; 915: 218-226 (Pubitemid 32947037)
158. Singh VP, Patil CS, Jain NK, Singh A, Kulkarni SK. Paradoxical effects of opioid antagonist naloxone on SSRI-induced analgesia and tolerance in mice. Pharmacology. 2003 ; 69: 115-122 (Pubitemid 37186727)
159. Sinha SS, Goetz RR, Klein DF. Physiological and behavioral effects of naloxone and lactate in normal volunteers with relevance to the pathophysiology of panic disorder. Psychiatry Res. 2007 ; 149: 309-314 (Pubitemid 46108096)
160. Soubrie P, Jobert A, Thiebot MH. Differential effects on naloxone against the diazepam-induced release of behavior in rats in three aversive situations. Psychopharmacology (Berl). 1980 ; 69: 101-105 (Pubitemid 10065179)
161. Stevens CW. Opioid research in amphibians: an alternative pain model yielding insights on the evolution of opioid receptors. Brain Res Brain Res Rev. 2004 ; 46: 204-215 (Pubitemid 39298867)
162. Szekely JI. Opioid peptides and stress. Crit Rev Neurobiol. 1990 ; 6: 1-12 (Pubitemid 20320175)
163. Tao R, Auerbach SB. Anesthetics block morphine-induced increases in serotonin release in rat CNS. Synapse. 1994 ; 18: 307-314 (Pubitemid 24357830)
164. Taylor DV, Boyajian JG, James N, et al. Acidosis stimulates beta-endorphin release during exercise. J Appl Physiol. 1994 ; 77: 1913-1918
165. Tejedor-Real P, Mico JA, Maldonado R, Roques BP, Gibert-Rahola J. Implication of endogenous opioid system in the learned helplessness model of depression. Pharmacol Biochem Behav. 1995 ; 52: 145-152
166. Thyer BA, Matthews J. The effect of phobic anxiety on plasma beta-endorphin: a single-subject experiment. Behav Res Ther. 1986 ; 24: 237-241 (Pubitemid 16126633)
167. Tsuda M, Suzuki T, Misawa M, Nagase H. Involvement of the opioid system in the anxiolytic effect of diazepam in mice. Eur J Pharmacol. 1996 ; 307: 7-14 (Pubitemid 26226277)
168. Urraca N, Camarena B, Gomez-Caudillo L, Esmer MC, Nicolini H. Mu opioid receptor gene as a candidate for the study of obsessive compulsive disorder with and without tics. Am J Med Genet B Neuropsychiatr Genet. 2004 ; 127B: 94-96 (Pubitemid 38542322)
169. van der Kolk BA, Greenberg MS, Orr SP, Pitman Rk. Endogenous opioids, stress induced analgesia, and posttraumatic stress disorder. Psychopharmacol Bull. 1989 ; 25: 417-421 (Pubitemid 20260250)
170. Veinante P, Stoeckel ME, Freund-Mercier MJ. GABA- and peptide-immunoreactivities co-localize in the rat central extended amygdala. Neuroreport. 1997 ; 8: 2985-2989 (Pubitemid 27394831)
171. Veith JL, Anderson J, Slade SA, Thompson P, Laugel GR, Getzlaf S. Plasma beta-endorphin, pain thresholds and anxiety levels across the human menstrual cycle. Physiol Behav. 1984 ; 32: 31-34 (Pubitemid 14179676)
172. Warneke L. A possible new treatment approach to obsessive-compulsive disorder. Can J Psychiatry. 1997 ; 42: 667-668 (Pubitemid 27397686)
173. Weinberger SE, Steinbrook RA, Carr DB, et al. Endogenous opioids and ventilatory responses to hypercapnia in normal humans. J Appl Physiol. 1985 ; 58: 1415-1420 (Pubitemid 15027033)
174. Weizman R, Gil-Ad I, Hermesh H, Munitz H, Laron Z. Immunoreactive beta-endorphin, cortisol, and growth hormone plasma levels in obsessive-compulsive disorder. Clin Neuropharmacol. 1990 ; 13: 297-302 (Pubitemid 20230324)
175. Williams TM, Davies SJC, Taylor LG, Daglish MR, Nutt DJ, Lingford-Hughes A. Can personality traits elucidate the relationship between substance dependence and opioid receptor availability?. Eur Neuropsychopharmacol. 2008 ; 18 (Suppl 4). S536 - S536
176. Wilson MA, Junor L. The role of amygdalar mu-opioid receptors in anxiety-related responses in two rat models. Neuropsychopharmacology. 2008 ; 33: 2957-2968
177. Wittmann W, Schunk E, Rosskothen I, et al. Prodynorphin-derived peptides are critical modulators of anxiety and regulate neurochemistry and corticosterone. Neuropsychopharmacology. 2009 ; 34: 775-785
178. You ZB, Godukhin O, Goiny M, et al. Cholecystokinin-8S increases dynorphin B, aspartate and glutamate release in the fronto-parietal cortex of the rat via different receptor subtypes. Naunyn Schmiedebergs Arch Pharmacol. 1997 ; 355: 576-581 (Pubitemid 27171216)
179. You ZB, Herrera-Marschitz M, Pettersson E, et al. Modulation of neurotransmitter release by cholecystokinin in the neostriatum and substantia nigra of the rat: regional and receptor specificity. Neuroscience. 1996 ; 74: 793-804 (Pubitemid 26285815)
180. You ZB, Pettersson E, Herrera-Marschitz M, et al. Modulation of striatal aspartate and dynorphin B release by cholecystokinin (CCK-8) studied in vivo with microdialysis. Neuroreport. 1994 ; 5: 2301-2304 (Pubitemid 24374860)
181. Zadina JE, Hackler L, Ge LJ, Kastin AJ. A potent and selective endogenous agonist for the mu-opiate receptor. Nature. 1997 ; 386: 499-502 (Pubitemid 27164076)
182. Zangen A, Nakash R, Yadid G. Serotonin-mediated increases in the extracellular levels of beta-endorphin in the arcuate nucleus and nucleus accumbens: a microdialysis study. J Neurochem. 1999 ; 73: 2569-2574
183. Zarrindast MR, Babapoor-Farrokhran S, Babapoor-Farrokhran S, Rezayof A. Involvement of opioidergic system of the ventral hippocampus, the nucleus accumbens or the central amygdala in anxiety-related behavior. Life Sci. 2008 ; 82: 1175-1181
184. Zarrindast MR, Rostami P, Zarei M, Roohbakhsh A. Intracerebroventricular effects of histaminergic agents on morphine-induced anxiolysis in the elevated plus-maze in rats. Basic Clin Pharmacol Toxicol. 2005 ; 97: 276-281 (Pubitemid 41608119)
185. Zhang HT, Xu ZM, Luo ZP, Qin BY. Anxiogenic effect of naltrexone in social interaction test in rats. Zhongguo Yao Li Xue Bao. 1996 ; 17: 314-317
186. Zhang Z, Schulteis G. Withdrawal from acute morphine dependence is accompanied by increased anxiety-like behavior in the elevated plus maze. Pharmacol Biochem Behav. 2008 ; 89: 392-403
187. Zhu W, Pan ZZ. Synaptic properties and postsynaptic opioid effects in rat central amygdala neurons. Neuroscience. 2004 ; 127: 871-879 (Pubitemid 39099552)
188. Zomkowski AD, Santos AR, Rodrigues AL. Evidence for the involvement of the opioid system in the agmatine antidepressant-like effect in the forced swimming test. Neurosci Lett. 2005 ; 381: 279-283 (Pubitemid 40719172)
189. Zubieta JK, Ketter TA, Bueller JA, et al. Regulation of human affective responses by anterior cingulate and limbic mu-opioid neurotransmission. Arch Gen Psychiatry. 2003 ; 60: 1145-1153 (Pubitemid 37429654)